Burshtein Gregory
Known title: Chief of R&DCIK: 0002026002
Associated companies
Transaction History
| ENTX | ▲ Buy | Grant | 87,591 | $0 | 5/7/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 26,316 | $0 | 7/16/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 87,591 | $0 | 5/7/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 26,316 | $0 | 7/16/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.